Use of androgens in postmenopausal women

Current Opinion in Obstetrics and Gynecology

Volumn 9, Issue 3, 1997, Pages 177-180

  Davis, Susan R ^a   Burger, Henry G ^b,c  

^a Jean Hailes Foundation for Women's Health   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

^c HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ESTROGEN;

ANDROGEN BLOOD LEVEL; BONE GROWTH; ESTROGEN THERAPY; FEMALE; HORMONAL THERAPY; HORMONE ACTION; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; TESTOSTERONE BLOOD LEVEL;

EID: 0030835693     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-199706000-00008     Document Type: Review

References (37)

1. Davis SR, Burger HG: Clinical review - androgens and the postmenopausal woman. J Clin Endocrinol Metab 1996, 81:2759-2763. The clinical use of androgen replacement therapy is discussed in terms of androgen physiology, the clinical benefits of androgen replacement, and potential risks.
2. Burger HG, Dudley EC, Hopper JL, Shelley JM, Green A, Smith A, Dennerstein L, Morse C: The endocrinology of the menopausal transition: a cross-sectional study of a population based sample. J Clin Endocrinol Metab 1996, 80:3537-3545. This is a report of the initial findings of the Melbourne Women's Midlife Health Study and provides a very important insight into the menopausal transition.
3. Zumoff B, Strain GW, Miller LK, Rosner W: Twenty-four hour mean plasma testosterone concentration declines with age in normal premenopausal women. J Clin Endocrinol Metab 1995, 80:1429-1430.
4. Zumoff B, Rosenfeld RS, Strain GW, Levin J, Fukushima DK: Sex differences in the 24-hour mean plasma concentrations of dehydroisoandrosterone (DHA) and dehydroisoandrosterone Sulfate (DHAS) and the DHA to DHAS ratio in normal adults. J Clin Endocrinol Metab 1980, 51:330-334.
5. Longcope C, Franz C, Morello C, Baker K, Johnston CC Jr: Steroid and gonadotropin levels in women during the peri-menopausal years. Maturitas 1986, 8:189-196.
6. Ushiroyama T, Sugimoto O: Endocrine function of the peri- and postmenopausal ovary. Horm Res 1995, 44:64-68.
7. Bancroft J, Cawood EHH: Androgens and the menopause; a study of 40-60 year old women. Clin Endocrinol 1996, 45:577-587. This study addresses the impact of the menopause, age, body mass index and smoking on circulating levels of ovarian and adrenal androgens in women aged 40-60 years. The findings for each of the hormones measured are clearly presented and individually discussed.
8. Mushayandebvu T, Castracane DV, Gimpel T, Adel T, Santoro N: Evidence for diminished midcycle ovarian androgen production in older reproductive aged women. Fertil Steril 1996, 65:721-723. This study demonstrates clearly a decline in mid-cycle androgen production with increasing reproductive age, but prior to the menopausal transition. The importance is in terms of the clinical sequelae of this often unrecognised hormonal change.
9. Tazuke S, Khaw K-T, Chir MBB, Barrett-Connor E: Exogenous estrogen and endogenous sex hormones. Medicine 1992, 71:44-51.
10. Mathur RS, Landgreve SC, Moody LO, Semmens JP, Williamson HO: The effect of estrogen treatment on plasma concentrations of steroid hormones, gonadotropins, prolactin and sex hormone-binding globulin in post-menopausal women. Maturitas 1985, 7:129-133.
11. Krug R, Psych D, Pietrowsky R, Fehm HL, Born J: Selective influence of menstrual cycle on perception of stimuli with reproductive significance. Psychosom Med 1994, 56:410-417.
12. Castelo-Branco C, Martinez de Osaba MJ, Fortuny A, Iglesias X, Gonzalez-Merlo J: Circulating hormone levels in menopausal women receiving different hormone replacement therapy regimens. A comparison. J Reprod Med 1995, 40:556-560.
13. Bixo M, Bäckström T, Winblad B, Andersson A: Estradiol and testosterone in specific regions of the human female brain in different endocrine states. J Steroid Biochem Mol Biol 1995, 55:297-303.
14. Roselli CE, Resko JA: Aromatase activity in the rat brain: hormone regulation and sex differences. J Steroid Biochem Mol Biol 1993, 44:499-508.
15. Van Goozen SHM, Cohen-Kettensis PT, Gooren LJG, Frijda NH, Van de Poll NE: Gender differences in behaviour: activating effects of cross-sex hormones. Psychoneuroendocrinology 1995, 20:343-363. This is a fascinating, detailed study of the effects of cross-sex hormone therapy in a transsexual population and is a must for anyone with an interest in this area.
16. Siemenda C, Longcope C, Peacock M, Hui S, Johnston CC: Sex steroids, bone mass, and bone loss. A prospective study of pre-, peri-, and postmenopausal women. J Clin Invest 1996, 97:14-21. This paper provides longitudinal data pertaining to the relationship between sex steroids and bone mass across the menopausal transition. It highlights the importance of androgens in the postmenopausal years.
17. Nilas L, Christiansen C: Bone mass and its relationship to age and the menopause. J Clin Endocrinol Metab 1987, 65:697-699.
18. Simberg N, Tiitinen A, Silfrast A, Viinikka L, Ylikorkala O: High bone density in hyperandrogenic women: effect of gonadotropin-releasing hormone agonist alone or in conjunction with estrogen-progestin replacement. J Clin Endocrinol Metab 1995, 81:646-651.
19. Watts NB, Notelovitz M, Timmons TC, Addison WA, Wiita B, Downey LJ: Comparison of oral estrogens plus androgen on bone mineral density menopausal symptoms and lipid-lipoprotein profiles in surgical menopause. Obstet Gynecol 1995, 85:529-537.
20. Davis SR, McCloud P, Strauss BJG, Burger HG: Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1995, 21:227-236.
21. Raisz LG, Wiita B, Artis A, Bowen A, Schwartz S, Trahiotis M, Shoukri K, Smith J: Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J Clin Endocrinol Metab 1996, 81:37-43. One of the few documentations of the effects of clinical androgen replacement therapy in women. The key findings are that oestrogen alone blocks bone reabsorption whereas the inclusion of androgen replacement additionally increases biochemical parameters of bone formation.
22. Kasra M, Grynpas MD: The effects of androgens on the mechanical properties of primate bone. Bone 1995, 17:265-270.
23. Colvard DS, Eriksen EF, Keeting PE, Wilson EM, Lubahn DB, French FS, Riggs B, Spelsberg TC: Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci USA 1989, 86:854-857.
24. Kasperk CH, Wergedal JE, Farley JR, Llinkhart TA, Turner RT, Baylink DG: Androgens directly stimulate proliferation of bone cells in vitro. Endocrinology 1989, 124:1576-1578.
25. Wiren KM, Keenan EJ, Orwoll ES: Regulation of androgen receptor promotor by androgens in osteoblastic cells [Abstract]. Proceedings of the 10th Internation Congress on Endocrinology. San Francisco, June 12-15. Bethesda, Maryland: The Endocrine Society Press; 1996: 188.
26. Cagnacci A, Mallus E, Tuveri F, Cirillo R, Setteneri AM, Melis GB: Effect of tibolone on glucose and lipid metabolism in postmenopausal women. J Clin Endocrinol Metab 1997, 82:251-253.
27. Wakatsuki A, Sagara Y: Lipoprotein metabolism in postmenopausal and oophorectomized women. Obstet Gynecol 1995, 85:523-528.
28. Barrett-Connor E, Goodman-Gruen D: Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women. BMJ 1995, 311:1193-1196.
29. Barrett-Connor E, Goodman-Gruen D: Dehydroepiandrosterone sulfate does not predict cardiovascular death in postmenopausal women. The Rancho Bernardo Study. Circulation 1995, 91:1757-1760.
30. Goodman-Gruen D, Barrett-Connor E: Total but not bioavailable testosterone is a predictor of central adiposity in postmenopausal women, Int J Obes 19:293-298.
31. Engelson ES, Goggin KJ, Rabkin JG, Kotler DP: Nutrition and testosterone status of HIV positive women. Proceedings of the XI International Conference on AIDS. Vancouver, July 7-12, 1996, 332:Po.Tu.B.2382.
32. Engelson ES, Rabkin JG, Rabkin R, Kotler DP: Effects of testosterone upon body composition [Letter]. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 11:510-511. Reversal of testosterone deficiency is shown to be associated with positive improvements in body composition in HIV sufferers in this preliminary report. It highlights an innovative direction for the management of HIV sufferers.
33. Secreto G, Toniolo P, Pisani P, Recchione C, Cavalleri A, Fariselli G, Totis A, Di Petro S, Berrino F: Androgens and breast cancer in premenopausal women. Cancer Res 1989, 49:471-476.
34. Secreto G, Toniolo P, Berrino F, Recchione C, Cavalleri A, Pisani P, Totis A, Fariselli G, Di Petro S: Serum and urinary androgens and risk of breast cancer in postmenopausal women. Cancer Res 1991, 51:2572-2576.
35. Berrino F, Muti P, Michelli A, Bolelli G, Krogh V, Sciajno R, Pisani P, Panico S, Secreto G: Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst 1996, 88: 291-296.
36. Recchione C, Venturelli E, Manzari A, Cavalteri A, Martinetti A, Secreto G: Testosterone, dihydrotestosterone, and oestradiol levels in postmenopausal breast cancer tissues. J Steroid Biochem Mol Biol 1995, 52:541-546. High intra-tumour levels of dihydrotestosterone and oestradiol were identified in breast cancer tissue. The conclusion from this study is that local hormone production is a key factor in breast cancer growth.
37. Bryan RM, Mercer RJ, Rennie GC, Lie TH, Morgan FJ: Androgen receptors in breast cancer. Cancer 1984, 54:2436-2440.